Abstract:Background The prevalence of inflammatory bowel disease (IBD) has been on the rise in developing countries. However, the mechanism of interaction between gut microbiota and immunity, especially how probiotics regulate the imbalance of mucosal immunity in IBD, remains unclear. Hence, this study aims to explore the role of Clostridium butyricum (C. butyricum) in M2 macrophage-mediated intestinal barrier injury repairation regarding the mechanism of efferocytosis. Methods C. butyricum was treated in DSS-induced colitis mice to observe the gut barrier and the macrophage phenotype (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (A) The flow chart of the experiment). The efferocytosis-related gene expression in terms of mucosal healing was explored in colitis mice with or without clodronate liposome treatment. RNA-sequencing was used to study the mechanism of C. butyricum on macrophage efferocytosis. Results We found that C. butyricum relieved intestinal inflammation and intestinal barrier injury in colitis mice (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (B,C) The wight loss and histological images of mice). M2 macrophages and the efferocytosis-related genes were upregulated after C. butyricum treatment (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (D-I) The frequency and efferocytosis-related genes expression of macrophage). Macrophage deletion induced by clodronate liposomes prevented the role of C. butyricum on the intestinal barrier and macrophage phenotype (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (J-M) The effect of C. butyricum after macrophage clearance). RNA-sequencing revealed differentially expressed genes upregulated and downregulated (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (A) The numbers of differentially expressed genes after C. butyricum treatment). KEGG enrichment results suggested that the PPAR pathway were significantly enriched and the expression of PPAR pathway-related genes was identified (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (B,C) The result of enrichment analysis and differentially expressed genes that enriched in PPAR pathway). C. butyricum upregulated the expression of PPARδ and PPARγ, not PPARα (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (D-F) The relative expression of genes). Furthermore, PPARγ inhibitor GW9662 instead of PPARδ inhibitor GSK3787 could prevent the role of C. butyricum in inflammation suppression and macrophage efferocytosis promotion (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (G,H) The weight loss and colon length of mice). Conclusions Our findings demonstrated that C. butyricum attenuated intestinal inflammation and barrier injury by promoting M2 macrophage polarization and efferocytosis, which is partly mediated by PPARγ activation.

Butyrate Inhibits the HDAC8/NF-κB Pathway to Enhance Slc26a3 Expression and Improve the Intestinal Epithelial Barrier to Relieve Colitis

Butyrate Attenuates Intestinal Inflammation in Crohn’s Disease by Suppressing Pyroptosis of Intestinal Epithelial Cells Via the Cgsa-Sting-nlrp3 Axis

Butyrate Prevents the Pathogenic Anemia‐Inflammation Circuit by Facilitating Macrophage Iron Export

Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis

Butyrate Protects Barrier Integrity and Suppresses Immune Activation in a Caco-2/PBMC Co-Culture Model While HDAC Inhibition Mimics Butyrate in Restoring Cytokine-Induced Barrier Disruption

P036 Faecalibacterium Prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1

P036 Microbiota Metabolite Butyrate Attenuates Intestinal Inflammation Through Autophagy Activation

Butyrate Functions in Concert with Myeloid-Derived Suppressor Cells Recruited by CCR9 to Alleviate DSS-induced Murine Colitis.

SCFAs induce autophagy in intestinal epithelial cells and relieve colitis by stabilizing HIF-1α

Butyrate Induces Intestinal Epithelial Cell to Express Thrombospondin 1 and Suppress Intestinal Mucosal Inflammation

Butyrate Prevents Induction of CXCL10 and Non-Canonical IRF9 Expression by Activated Human Intestinal Epithelial Cells via HDAC Inhibition

Butyrate alleviates murine colitis by promoting the expansion of myeloid-derived suppressor cells

Isosteviol Attenuates DSS-induced Colitis by Maintaining Intestinal Barrier Function Through PDK1/AKT/NF-κB Signaling Pathway

Sodium Butyrate Alleviates Mouse Colitis by Regulating Gut Microbiota Dysbiosis

Butyrate attenuates intestinal inflammation in Crohn's disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis

IDDF2024-ABS-0252 Clostridium Butyricum Attenuates Intestinal Barrier Injury by Promoting PPARγ-mediated Efferocytosis in Macrophages

Butyrate Inhibits Interleukin-17 and Generates Tregs to Ameliorate Colorectal Colitis in Rats

Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function

Butyrate Alleviates Cytokine-Induced Barrier Dysfunction by Modifying Claudin-2 Levels

BUTYRATE-INDUCED MITOCHONDRIAL FUNCTION IMPROVES BARRIER FUNCTION IN INFLAMMATORY BOWEL DISEASE (IBD)

Oat beta-glucan reduces colitis by promoting autophagy flux in intestinal epithelial cells via EPHB6-TFEB axis